AstraZeneca wolfs down Wall Street listing

No wonder shareholders wore broad grins. Not content with taking a huge bite out of the Big Apple, on this side of the Atlantic AZ's share price was up by around 2.7 per cent to 13,966p for a market cap of £218,26bn. The 52-week low in the UK is 9,573.50 a share. The stock was also charging ahead in Sweden.

Michel Demaré, Chair, AstraZeneca, said: "Today marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world.

"This will allow even more investors to participate in AstraZeneca’s future. Our harmonized listing across New York, London and Stockholm reflects strong shareholder support for our growth strategy and positions AstraZeneca to deliver more innovative medicines to more patients around the world."

Lynn Martin, President, NYSE Group said: “Today we are proud to welcome AstraZeneca to the NYSE, where it joins a community of groundbreakers and industry leaders. Through its listing on the world’s largest and most liquid capital market, the company is well-positioned to expand its global investor base and accelerate its commitment to delivering innovation to patients and the wider biopharmaceutical industry.”

AstraZeneca’s strong growth is driven both by its global reach and diverse sources of business. Last year was a catalyst-rich period with new pipeline readouts collectively representing a peak revenue opportunity of over $10 billion.

With this momentum continuing into 2026, the company has confidence in reaching its 2030 ambition to grow annual revenue to $80bn and launch 20 new medicines. Looking beyond 2030, AstraZeneca is investing in transformative technologies that have the potential to change the practice of medicine across its portfolio.